Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

[124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors.

Hall LT, Titz B, Baidya N, van der Kolk AG, Robins HI, Otto M, Perlman SB, Weichert JP, Kuo JS.

Mol Imaging Biol. 2019 Jun 10. doi: 10.1007/s11307-019-01362-1. [Epub ahead of print]

PMID:
31183841
2.

Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.

Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):878-886. doi: 10.1016/j.ijrobp.2018.11.008. Epub 2018 Nov 27.

PMID:
30496882
3.

Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity.

Nguyen HN, Vo KBH, Howard S, Salamat MS, Rowely H, Robins HI.

Neurooncol Pract. 2018 Nov;5(4):223-226. doi: 10.1093/nop/npx037. Epub 2018 Feb 2.

PMID:
30402261
4.

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide.

Robins HI, Nguyen HN, Field A, Howard S, Salamat S, Deming DA.

Front Oncol. 2018 Oct 15;8:451. doi: 10.3389/fonc.2018.00451. eCollection 2018.

5.

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.

Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A.

JAMA Oncol. 2018 Oct 1;4(10):1405-1409. doi: 10.1001/jamaoncol.2018.1977.

6.

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.

Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B.

Neurosurgery. 2019 Jan 1;84(1):66-76. doi: 10.1093/neuros/nyy003.

PMID:
29618054
7.

Survival of patients with prior anti-angiogenic therapy.

Eickhoff J, Robins HI.

Neuro Oncol. 2018 May 18;20(6):860-861. doi: 10.1093/neuonc/noy039. No abstract available.

8.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited.

Nguyen HTN, Grogan P, Robins HI.

Lancet Oncol. 2017 Dec;18(12):e708. doi: 10.1016/S1470-2045(17)30857-4. No abstract available.

PMID:
29208432
9.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

10.

PET/CT imaging of the diapeutic alkylphosphocholine analog 124I-CLR1404 in high and low-grade brain tumors.

Hall LT, Titz B, Robins HI, Bednarz BP, Perlman SB, Weichert JP, Kuo JS.

Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):157-166. eCollection 2017.

11.

Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404.

Besemer AE, Titz B, Grudzinski JJ, Weichert JP, Kuo JS, Robins HI, Hall LT, Bednarz BP.

Phys Med Biol. 2017 Jul 6;62(15):6008-6025. doi: 10.1088/1361-6560/aa716d.

PMID:
28682793
12.

The effect of Optune™ Tumor Treating Fields transducer arrays on skin radiation dose during radiotherapy.

Bender E, Kozak K, Howard S, Hayes L, Bayouth J, Robins HI.

J Clin Neurosci. 2017 Aug;42:172-175. doi: 10.1016/j.jocn.2017.04.002. Epub 2017 Apr 17.

PMID:
28427800
13.

Cancer-related cognitive impairment and its relation to PTSD.

Robins HI, Johnson L, LoConte N, Brandt K.

Breast. 2017 Aug;34:134. doi: 10.1016/j.breast.2017.03.005. Epub 2017 Mar 9. No abstract available.

PMID:
28285890
14.

Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.

Rajesh D, Robins HI, Howard SP.

J Neurol Neuromedicine. 2016;1(6):1-10.

15.

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M.

Neuro Oncol. 2017 Feb 1;19(2):252-258. doi: 10.1093/neuonc/now236. Erratum in: Neuro Oncol. 2017 Feb 1;19(2):e1.

16.

The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.

Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI.

J Clin Neurosci. 2017 Feb;36:120-124. doi: 10.1016/j.jocn.2016.10.042. Epub 2016 Nov 16.

17.

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD.

J Clin Oncol. 2016 Jul 20;34(21):2468-77. doi: 10.1200/JCO.2015.65.7825. Epub 2016 Jun 6.

18.

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.

Brower JV, Robins HI.

Expert Opin Pharmacother. 2016;17(7):1013-21. doi: 10.1517/14656566.2016.1165206. Epub 2016 Mar 30. Review.

PMID:
26967582
19.

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.

Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M.

J Neurooncol. 2016 Jan;126(2):309-16. doi: 10.1007/s11060-015-1966-z. Epub 2015 Oct 27.

20.

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.

Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY.

Cancer. 2015 Dec 1;121(23):4165-72. doi: 10.1002/cncr.29636. Epub 2015 Aug 26.

21.

Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.

Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, Robins HI, Bovi JA, Rockhill JK, Won M, Curran WP.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):961-7. doi: 10.1016/j.ijrobp.2014.12.050.

22.

Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.

Mehta MP, Wang D, Wang F, Kleinberg L, Brade A, Robins HI, Turaka A, Leahy T, Medina D, Xiong H, Mostafa NM, Dunbar M, Zhu M, Qian J, Holen K, Giranda V, Curran WJ.

J Neurooncol. 2015 Apr;122(2):409-17. doi: 10.1007/s11060-015-1733-1. Epub 2015 Feb 15.

PMID:
25682091
23.

Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS; CERN Foundation.

Neuro Oncol. 2015 Mar;17(3):440-7. doi: 10.1093/neuonc/nou162. Epub 2014 Aug 13.

24.

Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.

Boggs DH, Robins HI, Langer CJ, Traynor AM, Berkowitz MJ, Mehta MP.

Clin Lung Cancer. 2014 Nov;15(6):433-40. doi: 10.1016/j.cllc.2014.06.008. Epub 2014 Jun 24.

PMID:
25069747
25.

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4.

26.

ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases.

Expert Panel on Radiation Oncology-Brain Metastases, Lo SS, Gore EM, Bradley JD, Buatti JM, Germano I, Ghafoori AP, Henderson MA, Murad GJ, Patchell RA, Patel SH, Robbins JR, Robins HI, Vassil AD, Wippold FJ 2nd, Yunes MJ, Videtic GM.

J Palliat Med. 2014 Aug;17(8):880-6. doi: 10.1089/jpm.2014.9417. Epub 2014 Jun 27. Review.

27.

"TRIMing" the patient population to increase the benefit of mTOR inhibition.

Robins HI, Burkard ME, Halberg RB.

J Natl Cancer Inst. 2014 Apr 28;106(5). pii: dju095. doi: 10.1093/jnci/dju095. No abstract available.

PMID:
24777109
28.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

30.

Wide-field pulsed reduced dose rate radiotherapy (PRDR) for recurrent ependymoma in pediatric and young adult patients.

Mohindra P, Robins HI, Tomé WA, Hayes L, Howard SP.

Anticancer Res. 2013 Jun;33(6):2611-8.

PMID:
23749916
31.

Pseudoprogression after glioma therapy: a comprehensive review.

Kruser TJ, Mehta MP, Robins HI.

Expert Rev Neurother. 2013 Apr;13(4):389-403. doi: 10.1586/ern.13.7. Review.

PMID:
23545054
32.

Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.

Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD; Collaborative Ependymoma Research Network.

Brain Pathol. 2013 Sep;23(5):584-94. doi: 10.1111/bpa.12050. Epub 2013 Mar 28.

PMID:
23452038
33.

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski MK, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G, Suh JH, Mehta MP.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1312-8. doi: 10.1016/j.ijrobp.2012.11.042. Epub 2013 Feb 4.

34.

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.

Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J.

Target Oncol. 2013 Jun;8(2):117-25. doi: 10.1007/s11523-013-0254-0. Epub 2013 Jan 24.

35.

Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Leal T, Chang JE, Mehta M, Robins HI.

Curr Cancer Ther Rev. 2011 Nov;7(4):319-327.

36.

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11. doi: 10.1016/j.ijrobp.2012.10.008. Epub 2012 Nov 22.

37.

Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.

Sachidanandam K, Gayle AA, Robins HI, Kolesar JM.

J Oncol Pharm Pract. 2013 Sep;19(3):269-72. doi: 10.1177/1078155212461022. Epub 2012 Nov 15.

38.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY.

Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24.

39.

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY.

Clin Cancer Res. 2012 Nov 1;18(21):6032-9. doi: 10.1158/1078-0432.CCR-12-1841. Epub 2012 Aug 24.

40.

Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2012 Jun;14(6):761-7. doi: 10.1093/neuonc/nos065. Epub 2012 May 31.

41.

ACR Appropriateness Criteria® follow-up and retreatment of brain metastases.

Patel SH, Robbins JR, Gore EM, Bradley JD, Gaspar LE, Germano I, Ghafoori P, Henderson MA, Lutz ST, McDermott MW, Patchell RA, Robins HI, Vassil AD, Wippold FJ 2nd, Videtic GM; Expert Panel on Radiation Oncology–Brain Metastases.

Am J Clin Oncol. 2012 Jun;35(3):302-6. doi: 10.1097/COC.0b013e31824be246. Review.

PMID:
22609733
42.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

43.

Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.

Chao BH, Lepeak L, Leal T, Robins HI.

Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12.

44.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.

Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1.

45.

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2011 Oct;13(10):1118-24. doi: 10.1093/neuonc/nor110. Epub 2011 Aug 2.

46.

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS.

Neuro Oncol. 2011 Jun;13(6):649-59. doi: 10.1093/neuonc/nor040.

47.

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV.

Clin Cancer Res. 2011 Jul 15;17(14):4872-81. doi: 10.1158/1078-0432.CCR-11-0271. Epub 2011 Jun 1.

48.

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY.

J Clin Oncol. 2011 Jul 1;29(19):2689-95. doi: 10.1200/JCO.2010.34.1636. Epub 2011 May 23.

49.

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.

Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF; North American Brain Tumor Consortium.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1422-7. doi: 10.1016/j.ijrobp.2010.07.1997. Epub 2010 Oct 8.

50.

ACR Appropriateness Criteria: single brain metastasis.

Suh JH, Videtic GM, Aref AM, Germano I, Goldsmith BJ, Imperato JP, Marcus KJ, McDermott MW, McDonald MW, Patchell RA, Robins HI, Rogers CL, Wolfson AH, Wippold FJ 2nd, Gaspar LE.

Curr Probl Cancer. 2010 May-Jun;34(3):162-74. doi: 10.1016/j.currproblcancer.2010.04.003. Review.

PMID:
20541055

Supplemental Content

Loading ...
Support Center